Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
about
Circulating biomarkers in advanced renal cell carcinoma: clinical applicationsSorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorAssociation of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.Pharmacodynamic modelling of biomarker data in oncology.Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursModel-based treatment optimization of a novel VEGFR inhibitor.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTBridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies.A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.Quantifying the relationship between inhibition of VEGFR-2, drug-induced blood pressure elevation and hypertension.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.Tumor-independent host secretomes induced by angiogenesis and immune-checkpoint inhibitors.
P2860
Q27023770-B27828A0-6918-4E9C-9AB2-3ACDECFF2017Q30587082-31CA9B90-3FDF-4C13-8220-6B6CD9DCAA8DQ33432047-463EA9F8-7CDB-425D-A187-947834CFEEE9Q34013801-48C45E77-4DEB-4909-924D-269ED4DB3FDFQ34241935-1DF55473-D793-4C6E-9692-8F04FEA71BBCQ34953673-E97C8261-184C-47E7-8814-CECA81BA7294Q35104052-A88F1BD4-08CE-4F74-AB58-D3DAA9082AF4Q35274974-557161B1-6A5E-4BC0-B100-E253F82ADC94Q36779136-60E80D4E-3280-4438-B695-C87478D8DF56Q36987975-7FBD8CCA-CEDF-47E6-B5B3-6FAC2C1BBE25Q37366059-0AFA7A82-582E-408C-B837-9F69F390F550Q37461714-76FC790C-F01A-4FF3-9528-9084F50A3ADAQ38092582-EFAF07DD-D0BA-4448-B913-C3B4E0C9CEE9Q38378485-9562190C-A673-4D53-9EBE-1B4B09E80048Q38546217-7D5C482F-75A1-4038-AFBA-980EA050FFB2Q40126912-B9B36C5F-98DD-4A01-84F2-67D3DBAD9FEFQ40177329-4BF8A055-6767-4249-BBA9-66AB7203F9B6Q42418396-B1854046-C95F-4F80-A2A1-CBF8B6F59B8DQ43841175-AF0A1451-D548-46EE-8A1B-B71C58308F16Q43939236-F1117889-87AA-49A9-8678-E6E91B53364AQ47138419-22E937EA-B791-4DD4-8CCF-4D202074FA9FQ47434764-2A517751-ED25-477B-9AD9-06BAB67A50EEQ50600192-13ABE728-A5A5-4020-9539-54813C6D2DB7Q52562886-F5DBA89F-BAE0-4EA7-87EA-92A73E8729B6
P2860
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@ast
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@en
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@nl
type
label
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@ast
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@en
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@nl
prefLabel
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@ast
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@en
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@nl
P2093
P356
P1476
Pharmacokinetic/pharmacodynami ...... nitinib in healthy volunteers.
@en
P2093
A Lindauer
D Tomalik-Scharte
F Kanefendt
P304
P356
10.1038/CLPT.2010.20
P407
P577
2010-04-07T00:00:00Z